189 related articles for article (PubMed ID: 3689664)
21. Treatment of hypercalcemia of malignancy with intermittent single infusions of 3-amino-1-hydroxypropylidene-1, 1-biphosphonate (APD).
Rischin D; Bishop JF
Aust N Z J Med; 1988 Aug; 18(5):736-7. PubMed ID: 3245828
[No Abstract] [Full Text] [Related]
22. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
[TBL] [Abstract][Full Text] [Related]
23. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
[TBL] [Abstract][Full Text] [Related]
25. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
Body JJ; Louviaux I; Dumon JC
Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
[TBL] [Abstract][Full Text] [Related]
26. No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy.
Hené RJ; Visser WJ; Duursma SA; Raymakers JA; de bos Kuil RJ; Dorhout Mees EJ
Bone; 1990; 11(1):15-20. PubMed ID: 2331426
[TBL] [Abstract][Full Text] [Related]
27. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
van Holten-Verzantvoort AT; Bijvoet OL; Cleton FJ; Hermans J; Kroon HM; Harinck HI; Vermey P; Elte JW; Neijt JP; Beex LV
Lancet; 1987 Oct; 2(8566):983-5. PubMed ID: 2889957
[TBL] [Abstract][Full Text] [Related]
28. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
29. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
[TBL] [Abstract][Full Text] [Related]
30. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT
Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202
[TBL] [Abstract][Full Text] [Related]
31. Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
Reitsma PH; Bijvoet OL; Potokar M; van der Wee-Pals LJ; van Wijk-van Lennep MM
Calcif Tissue Int; 1983 May; 35(3):357-61. PubMed ID: 6871766
[TBL] [Abstract][Full Text] [Related]
32. An audit of the management of malignant hypercalcaemia.
Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA
Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360
[TBL] [Abstract][Full Text] [Related]
33. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
Wimalawansa SJ
Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347
[TBL] [Abstract][Full Text] [Related]
34. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
35. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).
Ling PJ; A'Hern RP; Hardy JR
Br J Cancer; 1995 Jul; 72(1):206-9. PubMed ID: 7599053
[TBL] [Abstract][Full Text] [Related]
36. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
Ralston SH; Alzaid AA; Gardner MD; Boyle IT
Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
[TBL] [Abstract][Full Text] [Related]
37. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
[TBL] [Abstract][Full Text] [Related]
38. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Fitton A; McTavish D
Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
[TBL] [Abstract][Full Text] [Related]
39. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
Coleman RE; Woll PJ; Miles M; Scrivener W; Rubens RD
Br J Cancer; 1988 Nov; 58(5):621-5. PubMed ID: 3219273
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of aminohydroxypropylidene diphosphonate in the treatment of malignancy-associated hypercalcaemia.
Stevens MJ
Med J Aust; 1987 Mar; 146(5):261-4. PubMed ID: 3821622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
